Royalty Pharma plc (RPRX) Stock: A Closer Look at the Analyst Ratings
Royalty Pharma plc (NASDAQ: RPRX) has a price-to-earnings ratio of 11.09x that is above its average ratio. Additionally, the 36-month beta value for RPRX is
Royalty Pharma plc (NASDAQ: RPRX) has a price-to-earnings ratio of 11.09x that is above its average ratio. Additionally, the 36-month beta value for RPRX is
Royalty Pharma plc (NASDAQ: RPRX)’s stock price has decreased by -1.21 compared to its previous closing price of 28.16. However, the company has seen a
The stock of Royalty Pharma plc (RPRX) has gone down by -3.39% for the week, with a -5.36% drop in the past month and a
The price-to-earnings ratio for Royalty Pharma plc (NASDAQ: RPRX) is 11.53x, which is above its average ratio. Moreover, the 36-month beta value for RPRX is
The price-to-earnings ratio for Royalty Pharma plc (NASDAQ: RPRX) is above average at 11.61x. The 36-month beta value for RPRX is also noteworthy at 0.45.
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.